Bristol-Myers Squibb (BMY) is back in focus after the FDA accepted its New Drug Application for mezigdomide, an oral CELMoD in combination therapy for relapsed or refractory multiple myeloma.

The FDA filing sits against a backdrop of improving sentiment in Bristol-Myers Squibb, with the stock at US$59.34 after a 1-year total shareholder return of 31.37% and an 11.00% year to date share price return, suggesting momentum has been building recently.

If this oncology update has you thinking about where the next wave of healthtech opportunities might come from, it could be worth scanning 40 healthcare AI stocks as a starting list of ideas.

Bristol-Myers Squibb now trades meaningfully above its recent lows, with fresh oncology momentum in the story and an estimated intrinsic value gap still flagged by some models. Does that mix still skew the risk reward toward buyers?

Most Popular Narrative: 5.7% Undervalued

With Bristol-Myers Squibb at $59.34 against a narrative fair value of $62.96, the current setup reflects a modest discount built on detailed earnings and margin assumptions.

Robust late-stage pipeline and ongoing life-cycle management for major brands, together with strategic partnerships (BioNTech, Philochem, Bain), expand the breadth of future regulatory approvals and label expansions, opening additional indications and helping to offset upcoming patent expiries, which underpins top-line and earnings growth.

Curious what revenue path, margin trajectory, and future P/E multiple are baked into that fair value? The narrative leans on precise forecasts and a tighter discount rate that could surprise you.

Result: Fair Value of $62.96 (UNDERVALUED)

However, Bristol-Myers Squibb still faces upcoming patent expiries on key drugs and pressure from drug pricing reforms, either of which could challenge the perception that the stock is currently undervalued.

Next Steps

The mix of optimism and concern around Bristol-Myers Squibb is hard to ignore. Consider reviewing the situation while sentiment is fresh and check the underlying details yourself using the 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Bristol-Myers Squibb?

If you are reassessing Bristol-Myers Squibb, it may be a useful time to widen the search and line up a few more watchlist candidates using focused screeners.

• Target income first by checking companies that appear in the 8 dividend fortresses for potential yield opportunities with more resilient payouts.
• Look for quality at a discount by reviewing the 46 high quality undervalued stocks that filters for stocks combining fundamentals with potential mispricing.
• Prioritise durability by scanning the 80 resilient stocks with low risk scores to spot businesses that currently carry lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.